BofA Securities downgraded Beta Bionics from Buy to Neutral
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/9/2026 | $24.00 | Buy | UBS |
| 1/27/2026 | $17.00 | Hold | TD Cowen |
| 1/9/2026 | Buy → Neutral | BofA Securities | |
| 10/21/2025 | $26.00 | Buy | Stifel |
| 10/1/2025 | $26.00 | Neutral → Buy | Goldman |
| 6/16/2025 | $26.00 | Buy | Truist |
| 6/12/2025 | $30.00 | Buy | Lake Street |
| 5/30/2025 | $16.00 | Neutral | Goldman |
8-K - Beta Bionics, Inc. (0001674632) (Filer)
8-K - Beta Bionics, Inc. (0001674632) (Filer)
SCHEDULE 13G/A - Beta Bionics, Inc. (0001674632) (Subject)
IRVINE, Calif., June 02, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (NASDAQ:BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that near real-time real-world data on the iLet Bionic Pancreas is now publicly available at betabionics.com/hcp/real-world-data. The dashboard publishes outcomes for 100% of the iLet patients who meet two simple, pre-stated criteria (a provider-reported baseline HbA1c and at least two weeks of data uploaded to the cloud), with no exclusions applied. Real-world data is a key reference point for clinicians weighing multiple automated insulin delivery (AID) options. Most of the evidence in the category arrives i
IRVINE, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (NASDAQ:BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that it expects to fully commercialize Mint by the end of the second quarter of 2027, subject to regulatory clearance by the U.S. Food and Drug Administration (FDA). The updated Mint commercialization timeline expectation is based on the FDA's initial responses to the company's Mint alternate controller enabled (ACE) insulin pump 510(k) application, and the progress the company has made in scaling its Mint manufacturing processes. The company expects manufacturing capacity to meet anticipated demand at launch.
IRVINE, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (NASDAQ:BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that management will present at the Bank of America Securities Health Care Conference in Las Vegas on Tuesday, May 12, 2026 at 2:20 pm Eastern Time (11:20 am Pacific Time). A live audio webcast of the presentation will be available on the Company's website in the "Investors—Events & Presentations" section at https://investors.betabionics.com, and will be archived there for future replay following the event. About Beta Bionics Beta Bionics, Inc. is a commercial-stage medical device company engaged in the des
4 - Beta Bionics, Inc. (0001674632) (Issuer)
4 - Beta Bionics, Inc. (0001674632) (Issuer)
4 - Beta Bionics, Inc. (0001674632) (Issuer)
4 - Beta Bionics, Inc. (0001674632) (Issuer)
4 - Beta Bionics, Inc. (0001674632) (Issuer)
UBS initiated coverage of Beta Bionics with a rating of Buy and set a new price target of $24.00
TD Cowen initiated coverage of Beta Bionics with a rating of Hold and set a new price target of $17.00
BofA Securities downgraded Beta Bionics from Buy to Neutral
MIAMI, Sept. 17, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NASDAQ:NSPR) ("InspireMD" or the "Company"), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced the appointment of Dan Dearen to its Board of Directors. Mr. Dearen brings nearly 40 years of leadership experience in the medical device and life sciences sectors, with a proven track record of guiding MedTech companies through critical financial milestones and delivering shareholder value through execution. "We are pleased to welcome Dan to InspireMD's Board of Directors," said Marvin Slosman, Chief Executive Officer of InspireMD. "He brings extensive experience, financial expertise, and
IRVINE, Calif., March 27, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (NASDAQ:BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced the appointment of Gerard Michel as an independent member of its board of directors, effective March 26, 2025. Mr. Michel is Chief Executive Officer of Delcath Systems (NASDAQ:DCTH), a commercial-stage interventional oncology company. "We are excited to welcome Gerard to the Beta Bionics Board," said Sean Saint, President and Chief Executive Officer of Beta Bionics. "Gerard is a highly regarded leader in the pharmaceutical and medical technology industries, and brings deep experience in driving innovation a
IRVINE, Calif., April 21, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (NASDAQ:BBNX), a pioneering leader in the development of advanced diabetes management solutions, today reported its financial results for the quarter ended March 31, 2026 and raised its full year guidance for the year ending December 31, 2026. First Quarter 2026 Financial Highlights & Key Metrics Net sales of $27.6 million, up 57% compared to $17.6 million in the first quarter of 2025. Durable Medical Equipment (DME) channel net sales of $16.9 million, up 22% compared to $13.8 million in the first quarter of 2025.Pharmacy Benefit Plan (PBP) channel net sales of $10.7 million, up 181% compared to $3.8 million in the fir
IRVINE, Calif., March 30, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (NASDAQ:BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that it plans to release its first quarter 2026 financial results after the financial markets close on Tuesday, April 21, 2026. Management will host a conference call and concurrent webcast on the same day at 4:30 pm Eastern Time (1:30 pm Pacific Time), to review the company's first quarter 2026 performance. The link to the webcast will be available on the Company's website in the "Investors—Events & Presentations" section at https://investors.betabionics.com, and will be archived there for future replay. To
IRVINE, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (NASDAQ:BBNX), a pioneering leader in the development of advanced diabetes management solutions, today reported its financial results for the quarter and year ended December 31, 2025 and introduced its annual guidance for the year ending December 31, 2026. Fourth Quarter 2025 Financial Highlights & Key Metrics Net sales of $32.1 million, up 57% compared to $20.4 million in the fourth quarter of 2024. Durable Medical Equipment (DME) channel net sales of $22.3 million, up 24% compared to $18.0 million in the fourth quarter of 2024.Pharmacy Benefit Plan (PBP) channel net sales of $9.8 million, up 295% compared to $2.5 mill